UBS AG Boosts Price Target on Par Pharmaceutical Companies Incorporated (PRX)

By admin | 6 years ago

UBS AG (NYSE: UBS) increased their price target on shares of Par Pharmaceutical Companies Incorporated (NYSE: PRX) from $42.00 to $48.00 in a research note issued on Wednesday. The firm currently has a “buy” rating on the stock.

A number of other analysts have also recently weighed in on PRX. Analysts at Needham & Company raised their price target on shares of Par Pharmaceutical Companies Incorporated from $42.00 to $48.00 in a research note to investors on Wednesday. They now have a “strong-buy” rating on the stock. Finally, analysts at Piper Jaffray (NYSE: PJC) initiated coverage on shares of Par Pharmaceutical Companies Incorporated in a research note to investors on Thursday, April 19th. They set an “overweight” rating on the stock.

Par Pharmaceutical Companies Incorporated traded down 0.90% on Wednesday, hitting $40.88. Par Pharmaceutical Companies Incorporated has a 1-year low of $24.85 and a 1-year high of $42.25. The company has a market cap of $1.499 billion and a price-to-earnings ratio of 27.56.

Par Pharmaceutical Companies Incorporated last released its earnings data on Tuesday, May 8th. The company reported $0.80 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.72 by $0.08. Par Pharmaceutical Companies Incorporated’s revenue was up 16.5% compared to the same quarter last year. Analysts expect that Par Pharmaceutical Companies Incorporated will post $1.10 EPS next quarter.

Par Pharmaceutical Companies, Inc., is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc.

About the author